{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Boan J"],"funding":["Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science, Innovation and Universities."],"pagination":["e70163"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12922572"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["69(2)"],"pubmed_abstract":["<h4>Background</h4>Echinocandins are the first-line treatment for invasive candidiasis. Rezafungin is a novel echinocandin with improved pharmacokinetic properties that allow for once-weekly intravenous administration, offering potential advantages in complex clinical settings.<h4>Objectives</h4>We aimed to describe our real-world experience with rezafungin for the treatment of invasive fungal disease (IFD).<h4>Patients</h4>A retrospective analysis of consecutive patients treated with rezafungin for proven IFD at our center between September 2022 and December 2025 was conducted.<h4>Results</h4>We included 13 patients (mean age: 59.4 ± 17.8 years). Main predisposing conditions included immunosuppression (53.8% [solid organ transplantation in 30.8%]), solid cancer (30.8%) and recent surgical"],"journal":["Mycoses"],"pubmed_title":["Rezafungin for Salvage or Consolidation Therapy of Invasive Fungal Disease: Experience in Real-World Clinical Practice."],"pmcid":["PMC12922572"],"funding_grant_id":["CM25/00250","CM25/00243","JR24/00034"],"pubmed_authors":["Perez-Ayala A","Perez-Jacoiste Asin MA","Caro-Teller JM","Aguado JM","San-Juan R","Lopez-Medrano F","Boan J","Fernandez-Ruiz M","Rodriguez-Goncer I","Aparicio-Minguijon E","Silva JT"],"additional_accession":[]},"is_claimable":false,"name":"Rezafungin for Salvage or Consolidation Therapy of Invasive Fungal Disease: Experience in Real-World Clinical Practice.","description":"<h4>Background</h4>Echinocandins are the first-line treatment for invasive candidiasis. Rezafungin is a novel echinocandin with improved pharmacokinetic properties that allow for once-weekly intravenous administration, offering potential advantages in complex clinical settings.<h4>Objectives</h4>We aimed to describe our real-world experience with rezafungin for the treatment of invasive fungal disease (IFD).<h4>Patients</h4>A retrospective analysis of consecutive patients treated with rezafungin for proven IFD at our center between September 2022 and December 2025 was conducted.<h4>Results</h4>We included 13 patients (mean age: 59.4 ± 17.8 years). Main predisposing conditions included immunosuppression (53.8% [solid organ transplantation in 30.8%]), solid cancer (30.8%) and recent surgical","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T15:12:27.16Z","creation":"2026-07-09T11:04:10.205Z"},"accession":"S-EPMC12922572","cross_references":{"pubmed":["41718446"],"doi":["10.1111/myc.70163"]}}